A Double-Blind Placebo-Controlled Dose-Response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-Mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma.

Trial Profile

A Double-Blind Placebo-Controlled Dose-Response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-Mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2013

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic conjunctivitis; Allergic rhinitis; Grass pollen hypersensitivity
  • Focus Adverse reactions
  • Acronyms ADRET
  • Most Recent Events

    • 15 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from recruiting to active, no longer recruiting.
    • 06 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top